Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 10/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.40 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.40 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924320 | 0.85 | DHODH (0.54) | DHODHSLC6A3NR4A2JMJD7NR4A1 | |
| SCHEMBL517998 | 0.85 | DHODH (0.54) | DHODHSLC6A3KMT2ANPC1POLB | |
| SCHEMBL3915696 | 0.81 | PTGS2 (0.43) | DHODH | |
| SCHEMBL3923666 | 0.80 | DHODH (0.39) | DHODHKMT2ANPC1 | |
| SCHEMBL3918039 | 0.75 | DHODH (0.41) | DHODHSLC6A3NR4A2JMJD7NR4A1 | |
| SCHEMBL6814731 | 0.74 | DHODH (0.49) | DHODHSLC6A3NR4A2JMJD7NR4A1 | |
| SCHEMBL3924512 | 0.73 | DHODH (0.72) | DHODHSLC6A3NR4A2JMJD7NR4A1 | |
| SCHEMBL3915666 | 0.73 | DHODH (0.46) | DHODHSLC6A3NR4A2JMJD7NR4A1 | |
| SCHEMBL6503513 | 0.71 | SLC6A3 (0.69) | DHODHSLC6A3KMT2ACA1CA2 | |
| SCHEMBL3914186 | 0.71 | DHODH (0.56) | DHODHSLC6A3NR4A2JMJD7NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | claimed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | Panoptes Hparma GmbH (AT) | 2017-02-02 | — | — | US | disclosed |
| WO-2015154820-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GMBH (AT) | 2015-10-15 | — | — | WO | disclosed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | DHODH 2305/4885SLC6A3 2759/4885NR4A2 2709/4885 |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, RPL35, NFKBIA | DHODH 2832/4885SLC6A3 4722/4885NR4A2 3102/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | DHODH 2796/4885SLC6A3 4778/4885NR4A2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.